All News
Filter News
Found 2,468 articles
-
Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa
10/12/2023
UCB, a global biopharmaceutical company, today announced the first analyses of pooled data from the two Phase 3 bimekizumab studies (BE HEARD I and BE HEARD II) in moderate-to-severe hidradenitis suppurativa (HS).
-
Zevra Therapeutics Appoints Neil F. McFarlane as President, Chief Executive Officer and Director
10/10/2023
Zevra Therapeutics, Inc. today announced that Neil F. McFarlane has been named President and Chief Executive Officer of Zevra and appointed to the Board of Directors, effective October 10, 2023.
-
New Investigational Drug Offers Relief for Treatment-Resistant Epilepsy Patients
10/9/2023
In cases where standard therapies fail, an investigational medication called XEN1101 reduces seizure frequency by more than 50% in some patients and sometimes eliminates them altogether, a new study shows.
-
Peptone Expands Leadership Team with Key Executive Hires
9/28/2023
Peptone, a leader in translational biophysics and the design of novel therapeutics against intrinsically disordered proteins, announced the appointment of key leaders to its Executive Management Team and Board of Directors.
-
Arcutis Appoints L. Todd Edwards as Chief Commercial Officer
9/27/2023
Arcutis Biotherapeutics, Inc. today announced the appointment of Todd Edwards as Chief Commercial Officer (CCO), effective immediately.
-
Shares were up over 60% in premarket trading on news that the company’s anti-FcRn antibody exhibited dose-dependent reductions in IgG levels, drivers of inflammation in many autoimmune diseases.
-
Scinai Immunotherapeutics Innovative Plaque Psoriasis Treatment Shows Encouraging Preclinical Results
9/13/2023
Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) today announces encouraging results in a preclinical study of Scinai’s anti‑interleukin 17 (IL‑17) NanoAbs as a treatment for plaque psoriasis.
-
OpenFold AI Research Consortium Welcomes Three New Members: UCB, NVIDIA and Valence Labs
9/12/2023
OpenFold, a non-profit artificial intelligence (AI) research consortium whose goal is to develop free and open-source software tools for biology and drug discovery
-
ALX Oncology Realigns Executive Leadership Team
9/6/2023
ALX Oncology Holdings Inc. today announced that Jason Lettmann, a member of the Board of Directors, will succeed Jaume Pons, Ph.D. as Chief Executive Officer, effective September 6, 2023.
-
Press Release: Sanofi announces changes to its Executive Committee
8/31/2023
Houman, Madeleine and Emmanuel will report to Sanofi's CEO, Paul Hudson, and will be based in Paris, France.
-
Treace Medical Concepts Appoints Nathan Minnich as Senior Vice President, Marketing
8/21/2023
Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty ® 3D Bunion Correction™ Procedure, today announced Nathan Minnich has been appointed Sr. Vice President, Marketing, effective immediately.
-
IO Biotech Appoints Heidi Hunter to its Board of Directors
8/11/2023
IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, announced the appointment of Heidi Hunter to its board of directors.
-
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2023 Financial Results
8/9/2023
Praxis Precision Medicines , Inc. today provided a corporate update and reported financial results for the second quarter 2023.
-
Xenon Pharmaceuticals Expands Leadership on its Board of Directors with Appointments of Gillian M. Cannon and Justin Gover
8/8/2023
Xenon Pharmaceuticals Inc. announced two new appointments to its Board of Directors: Dr. Gillian M. Cannon and Mr. Justin Gover. Dr. Cannon has more than 30 years of experience in the pharmaceutical industry, where she served in business and commercial leadership roles at Merck and Co., UCB, Otsuka and Roivant.
-
OMass Therapeutics Expands Leadership Team with Two New Appointments
8/2/2023
OMass Therapeutics, a biotechnology company that identifies medicines against highly validated target ecosystems, announces the expansion of its leadership team with the appointment of two senior executives in newly created roles.
-
Syndax and Incyte Announce Positive Topline Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease
7/24/2023
Syndax Pharmaceuticals (Nasdaq: SNDX) and Incyte (Nasdaq: INCY) today announced positive topline data from the pivotal AGAVE-201 trial of axatilimab, an anti-CSF-1R antibody, in adult and pediatric patients with chronic graft-versus-host disease (GVHD) following two or more prior lines of therapy.
-
Editas Medicine Strengthens Executive Leadership Team with Appointment of Linda C. Burkly, Ph.D., as Chief Scientific Officer
7/24/2023
Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the appointment of Linda C. Burkly, Ph.D., as the Company’s Executive Vice President and Chief Scientific Officer.
-
UCB announces U.S. availability of RYSTIGGO® (rozanolixizumab-noli) for the treatment of generalized myasthenia gravis (gMG)
7/21/2023
UCB, a global biopharmaceutical company, today announced that RYSTIGGO is commercially available for the treatment of adult patients in the U.S. with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.
-
Data Published in Transplantation and Cellular Therapy Suggest Antiviral Protection After Transplantation with Gamida Cell’s Omisirge® (omidubicel-onlv)
7/11/2023
Gamida Cell Ltd. today announced the publication in press of a prospective sub-study of the Phase 3 clinical trial for Omisirge® (omidubicel-onlv), the company’s allogeneic stem cell transplant therapy, characterizing immune reconstitution kinetics following hematopoietic stem cell transplantation (HCT) with Omisirge compared to umbilical cord blood (UCB).
-
Cytovation appoints Olav Hellebø to its Board of Directors
7/5/2023
Cytovation ASA, a clinical stage immune-oncology company focused on the development of its first-in-class targeted tumor membrane immunotherapy CyPep-1, announces the appointment of Olav Hellebø to its Board of Directors.